Pharma Prosecutions Begin to Pay for Themselves


In what may prove to be a tipping point for prosecutions against pharmaceutical companies, states are beginning to see their “enforcement efforts pay for themselves,” according to an article yesterday in Pharmalot. A report by Public Citizen details more than $10 billion in financial penalties awarded against pharmaceuticals from November 2011 to July 2012, and attributes the spate to the initiative of individual state attorneys general and, most importantly, the whistleblower provisions of the federal False Claims Act.

Article →

Of further interest:
State Settlements With Drug Companies Over Medicaid Fraud Are at Record Highs; Many States Recover More Than They Spent on Enforcement

Previous articleTransforming the Traditional Mental Health System Through Peer Staffed Respite Programs
Next articleClinical Intuition, Clinical Trials, and the Library at Alexandria
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].